APTOSE BIOSCIENCES INC (APTO) Stock Price, Quote, News and Overview
NASDAQ:APTO - Nasdaq - CA03835T3091 - Common Stock - Currency: USD
APTO Quote, Performance and Key Statistics
NASDAQ:APTO (3/7/2025, 8:05:19 PM)
3.17
+0.22 (+7.46%)
The current stock price of APTO is 3.17 USD. In the past month the price decreased by -43.01%. In the past year, price decreased by -93.52%.
APTO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About APTO
Company Profile
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Company Info
APTOSE BIOSCIENCES INC
251 Consumers Rd Suite 1105
North York ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 35
Company Website: https://aptose.com/
Investor Relations: https://www.aptose.com/investors
Phone: 16474799828
APTOSE BIOSCIENCES INC / APTO FAQ
What is the stock price of APTOSE BIOSCIENCES INC today?
The current stock price of APTO is 3.17 USD. The price increased by 7.46% in the last trading session.
What is the ticker symbol for APTOSE BIOSCIENCES INC stock?
The exchange symbol of APTOSE BIOSCIENCES INC is APTO and it is listed on the Nasdaq exchange.
On which exchange is APTO stock listed?
APTO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APTOSE BIOSCIENCES INC stock?
7 analysts have analysed APTO and the average price target is 122.4 USD. This implies a price increase of 3761.2% is expected in the next year compared to the current price of 3.17. Check the APTOSE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APTOSE BIOSCIENCES INC worth?
APTOSE BIOSCIENCES INC (APTO) has a market capitalization of 6.78M USD. This makes APTO a Nano Cap stock.
How many employees does APTOSE BIOSCIENCES INC have?
APTOSE BIOSCIENCES INC (APTO) currently has 35 employees.
What are the support and resistance levels for APTOSE BIOSCIENCES INC (APTO) stock?
APTOSE BIOSCIENCES INC (APTO) has a resistance level at 3.18. Check the full technical report for a detailed analysis of APTO support and resistance levels.
Should I buy APTOSE BIOSCIENCES INC (APTO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APTO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APTO, evaluating the profitability, health, valuation and growth aspects
- APTOSE BIOSCIENCES INC (APTO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APTOSE BIOSCIENCES INC (APTO) Sales and EPS estimates to see what analysts future expectations are.
- APTOSE BIOSCIENCES INC (APTO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APTOSE BIOSCIENCES INC (APTO) Insider and Institutional Ownership to learn about the owners and their transactions.
- APTOSE BIOSCIENCES INC (APTO) Stock Chart to make your own analysis
- APTOSE BIOSCIENCES INC (APTO) Latest news and press-releases to stay up to date.
Does APTOSE BIOSCIENCES INC (APTO) stock pay dividends?
APTO does not pay a dividend.
When does APTOSE BIOSCIENCES INC (APTO) report earnings?
APTOSE BIOSCIENCES INC (APTO) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of APTOSE BIOSCIENCES INC (APTO)?
APTOSE BIOSCIENCES INC (APTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-26.17).
APTO Technical Analysis
APTO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APTO. APTO may be in some trouble as it scores bad on both profitability and health.
APTO Financial Highlights
Over the last trailing twelve months APTO reported a non-GAAP Earnings per Share(EPS) of -26.17. The EPS decreased by -230.01% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APTO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to APTO. The Buy consensus is the average rating of analysts ratings from 7 analysts.